In a recent announcement by Imuron they state:
The FDA on the 26 May 2020 issued guidance explaining how the coronavirus disease public health emergency is impacting the conduct of formal meetings and its review of certain user fee-funded applications. The FDA will focus its resources on applications and submissions related to Covid-19 and other life-threatening conditions.
Any thoughts on whether this will impact plans to get a review of Acne phase 2?
Where have the shorters gone?, page-20
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 34.0¢ | 32.0¢ | $1.776M | 5.339M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 118187 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 698385 | 8 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |